Cancer Mechanisms

项目总结/摘要 Tisch癌症研究所（TCI）的癌症机制（CM）项目由49名成员组成， 有一个共同的目标，即与癌症相关机制发现相关的基础研究， 最终目标是产生新的知识，从而改善诊断、治疗和预防 原发性癌症和全身性癌症复发在我们独特的集水区在三个关键主题：1。 细胞与生态位生物学，2。信号网络和3。染色质与基因 法规（见研究策略中的图1）。 CM的主要研究者代表15个部门和10个研究所。截至2019年2月，CM计划 成员被授予超过1700万美元的直接成本资金，与NCI的支持470万美元和同行， 审查了与癌症有关的1 370万美元支助。2018年，该计划发表了82篇论文，其中22%是 17%为方案内，17%为方案间。 我们的前提是，基础研究集中在遗传，表观遗传，生物化学，微环境， 驱动原发性癌症发生和维持的发展途径，微小残留病， 休眠和明显的转移，将揭示新的生物标志物和治疗靶点，以解决这些问题 在液体和实体肿瘤之间的阶段。我们的目标是阐明跨三个CM的关键机制 主题，促进项目内和项目间的合作，以加速将发现转移到 翻译和临床工作。我们将通过协调一致的方案内努力， CM主题（例如工作组、月度会议），以及与其他组织的跨计划合作 癌症临床研究（CCI），癌症预防和控制（CPC）和癌症 免疫学（CI）或疾病焦点组，如肝癌。特别是，我们的新战略计划 允许CM研究者在确定治疗干预的靶点、生物标志物或分子后， 与新创建的CCI计划密切相关，该计划有助于加速翻译或临床路径。 最后，我们的战略计划将促进新的合作研究，培训和教育机会， 我们的计划和我们的社区（通过与CPC的努力），高影响力的出版物，MPI/P01提交， 通过与CCI的合作进行临床试验和翻译输出，以及其他团队的努力， CM的特殊科学。

PROJECT SUMMARY/ABSTRACT The Cancer Mechanisms (CM) Program of The Tisch Cancer Institute (TCI) is comprised of 49 members who share a common goal to catalyze basic research pertinent to cancer-relevant mechanistic discovery with the ultimate goal of generating new knowledge that will lead to improving the diagnosis, treatment, and prevention of primary cancer and systemic cancer recurrence in our unique catchment area across three key themes: 1. CELL AND NICHE BIOLOGY, 2. CELL SIGNALING NETWORKS and 3. CHROMATIN AND GENE REGULATION (see Figure 1 in the Research Strategy). Principal investigators in CM represent 15 Departments and 10 Institutes. As of February 2019, CM program members were awarded over $17 million in direct cost funding, with NCI support of $4.7 million and peer- reviewed cancer-related support of $13.7 million. In 2018, the program published 82 papers of which 22% were intra- and 17% were inter-programmatic. Our premise is that basic research focused on genetic, epigenetic, biochemical, micro-environmental, and developmental pathways that drive primary cancer initiation and maintenance, minimal residual disease, dormancy and overt metastasis, will reveal novel biomarkers and therapeutic targets to address each of these stages across both liquid and solid tumors. We aim to elucidate critical mechanisms across the three CM themes and foster intra- and inter-program collaborations in order to accelerate the transfer of discoveries into translational and clinical efforts. We will achieve this goal using orchestrated intra-programmatic efforts within CM themes (e.g. working groups, monthly meetings), and inter-programmatic collaborations with other programs such as Cancer Clinical Investigation (CCI), Cancer Prevention and Control (CPC) and Cancer Immunology (CI) or with disease focus groups such as Liver Cancer. In particular, our new strategic plan allows CM investigators, upon identifying targets, biomarkers or molecules for therapeutic intervention, to work closely with the newly created CCI program, which facilitates an accelerated translational or clinical path. Finally, our strategic plan will facilitate new collaborative research, training and education opportunities within our program and in our community (via efforts with CPC), high-impact publications, MPI/P01 submissions, clinical trials and translational output through partnership with CCI, and other team efforts that encompass CM's exceptional science.